Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
with the same aim of the elective one, may be offered to those patients,
improving their survival.References 1 Yendamuri S, Gold D, Jayaprakash V,
Dexter E, Nwogu C, Demmy T: Is sublobar resection sufficient for carcinoid
tumors? Ann Thorac Surg. 2011;92:1774-1778 2 Ferguson MK, Landreneau
RJ, Hazelrigg SR, Altorki NK, Naunheim KS, Zwischenberger JB, Kent M, Yim
AP: Long-term outcome after resection for bronchial carcinoid tumors.
Eur J Cardiothorac Surg. 2000;18:156-61 3 Detterbeck FC: Management of
carcinoid tumors. Ann Thorac Surg 2010;89:998-1005 4 Lardinois D, De Leyn
P, Van Schil P, Porta RR, Waller D, Passlick B, Zielinski M, Lerut T, Weder W:
ESTS guidelines for intraoperative lymph node staging in non-small cell
lung cancer. Eur J Cardiothorac Surg. 2006;30:787-792 5 Lim E, Yap YK, De
Stavola BL, Nicholson AG, Goldstraw P: The impact of stage and cell type on
the prognosis of pulmonary neuroendocrine tumors. J Thorac Cardiovasc
Surg. 2005;130:969-972 6 Daddi N, Ferolla P, Urbani M, Semeraro A, Avenia N,
Ribacchi R, Puma F, Daddi G: Surgical treatment of neuroendocrine tumors
of the lung. Eur J Cardiothorac Surg. 2004;26:813-817 7 Filosso PL, Ferolla P,
Guerrera F, Ruffini E, Travis WD, Rossi G, Lausi PO, Oliaro A; European Society
of Thoracic Surgeons Lung Neuroendocrine Tumors Working-Group Steering
Committee: Multidisciplinary management of advanced lung neuroendocrine
tumors. J Thorac Dis. 2015;7(Suppl 2):S163-S171 8 Filosso PL, Oliaro A, Ruffini
E, Bora G, Lyberis P, Asioli S, Delsedime L, Sandri A, Guerrera F: Outcome
and prognostic factors in bronchial carcinoids: a single-center experience.
J Thorac Oncol. 2013;8:1282-1288 9 Caplin ME, Baudin E, Ferolla P, Filosso P,
Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS
consensus conference participants: Pulmonary neuroendocrine (carcinoid)
tumors: European Neuroendocrine Tumor Society expert consensus and
recommendations for best practice for typical and atypical pulmonary
carcinoids. Ann Oncol. 2015;26:1604-1620 10 Öberg K, Hellman P, Ferolla P,
Papotti M; ESMO Guidelines Working Group: Neuroendocrine bronchial and
thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 2012;23 Suppl 7:vii120-vii123
SESSION ED05: THE 8TH EDITION OF THE TNM STAGING
SYSTEM
MONDAY, DECEMBER 5, 2016 - 16:00-17:30
ED05.01 WHAT’S NEW IN LUNG CANCER STAGING?
Hisao Asamura
Division of Thoracic Surgery, Keio University School of Medicine, Tokyo/Japan
The tumor, node and metastasis (TNM) classification for malignant tumors
has been periodically revised in the International Union for Cancer Control
(UICC) and American Joint Committee on Cancer (AJCC). As for lung cancer,
the process of revision is quite unique compared with malignancies of other
organs in that the corresponding professional society, the International
Association for the Study of Lung Cancer (IASLC), has been playing a principal
role in database construction, making revision agenda, simulation, and
validation as a proposal to UICC and AJCC. The agenda articles have been
already published for T, N, M, and stage grouping in the official journal
of IASLC. In brief, the IASLC database included 77,156 evaluable patients
diagnosed with lung cancer from 1999 to 2010, originating from 35 different
databases in 16 countries of 5 continents. Among these, the data of 3905
patients were given by electric data capturing. In the T descriptors, new
tumor-size groups were created: T1a 1-2 cm; T1c >2-3cm; T2a
>3-4cm; T2b >4-5cm; T3 >5-7cm; and T4 >7cm. Endobronchial l ocation